MTS3USA

REMARKS/ARGUMENTS

After entry of this paper, claims 33 and 47-53 are pending. Claims 54-60 are canceled, without prejudice, in an effort to place the application in condition for allowance. Applicants reserve the right to prosecute the canceled claims, as well as any subject matter canceled during prosecution of this application, in a divisional or continuation application filed during the pendency of this application.

35 USC § 112, First Paragraph Rejections

(i) Claims 54-56 are rejected under 35 USC § 112, first paragraph.

The Examiner asserted that the specification does not provide support for the recited fragments.

The cancellation of claims 54-56 moots the outstanding rejection.

(ii) Claim 57 is rejected under 35 USC § 112, first paragraph.

The Examiner asserted that the specification does not disclose a RNA sequence represented by the sequence of SEQ ID NO: 13 in which the T is replaced with U. The Examiner also asserted that the specification fails to teach a method to make the RNA represented by SEQ ID NO:13, or how to use such RNA molecule.

The cancellation of claim 57 moots the outstanding rejection.

(iii) Claims 58-60 are rejected under 35 USC § 112, first paragraph.

The Examiner asserted that while the specification discloses one KLK-L2 protein having the genomic sequence of SEQ ID NO:13, the specification fails to disclose any other nucleic acids of various sizes that hybridize to SEQ ID NO: 13 that encode the KLK-K2 protein which possess serine protease function.

The cancellation of claims 58-60 moots the outstanding rejection.

MT\$3U\$A

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON Attorneys for Applicants

By Yncy E. Bek Mary E. Bak

Registration No. 31,215

Spring House Corporate Center

Box 457

Spring House, PA 19477

(215) 540-9200